Medical research

Experimental drug delivers one-two punch to vision loss

In studies with lab-grown human cells and in mice, Johns Hopkins Medicine researchers have found that an experimental drug may be twice as good at fighting vision loss as previously thought.

Diabetes

Statin therapy reduces risk for diabetic retinopathy in T2DM

(HealthDay)—For Taiwanese patients with type 2 diabetes and dyslipidemia, statin therapy is associated with a reduced risk for diabetic retinopathy, according to a study published online Jan. 10 in JAMA Ophthalmology.

Ophthalmology

Intravitreal anti-VEGF use not tied to systemic adverse events

(HealthDay)—Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment is not associated with increased risk of systemic adverse events for patients with neovascular age-related macular degeneration, diabetic ...

Ophthalmology

Repeated ranibizumab doesn't impair macular perfusion

(HealthDay)—For patients with diabetic macular edema, repeated ranibizumab treatment does not appear to be associated with impaired macular perfusion, according to a study published online March 1 in JAMA Ophthalmology.

Ophthalmology

Persistent DME more likely with bevacizumab treatment

(HealthDay)—For patients with diabetic macular edema (DME), persistence is more likely with bevacizumab than with aflibercept or ranibizumab, according to a study published online Feb. 1 in JAMA Ophthalmology.

page 3 from 7